Expiring contracts
Public awards with modeled positioning windows.
Department of Health and Human Services$36.4MEnds Jun 29, 202775% recompete estimate
TASK ORDER AWARD- PHASE I CLINICAL TRIALS FOR THE DEVELOPMENT OF NEUROTHERAPEUTICS- DTI-117 IN HEALTHY VOLUNTEERS/SAD AND MAD CTDepartment of Health and Human Services$116.4KEnds Apr 28, 202750% recompete estimate
FDABAA-24-00123, REF # FY24C1EP6, CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME PATIENT-REPORTED OUTCOME (PRO) BURDEN MEASUREDepartment of Health and Human Services$724.5KEnds Jul 15, 202765% recompete estimate
BAA-FY24C3CP5-UNDERSTANDING HETEROGENEITY IN PREFERENCES FOR CLINICAL TRIAL PARTICIPATION IN DIVERSE PATIENT POPULATIONS.Department of Health and Human Services$1.3MEnds Nov 22, 202760% recompete estimate
REGULATORY MANAGEMENT CENTER (RMC)Department of Health and Human Services$17.4MEnds Oct 31, 202860% recompete estimate
DAIDS MONITORING FOR 1 PHASE III STUDY: A5300B/I2003B (PHOENIX)Department of Health and Human Services$3.1MEnds Dec 14, 202855% recompete estimate
REGULATORY CONSULTING ASSISTANCE FOR MEDICAL DEVICE DEVELOPER. RESEARCH AND DEVELOPMENT FOR CLINICAL STUDIES IN THE BLUEPRINT MEDTECH. PRE-SUBMISSION ASSESSMENT & PACKAGE PREPARATION. TASK ORDER 03. 04/09/2024 - 04/08/2029.Department of Health and Human Services$370.6KEnds Apr 8, 202955% recompete estimate
RESEARCH AND DEVELOPMENT FOR CLINICAL STUDIES IN THE BLUEPRINT MEDTECH. CLINICAL STUDY PROTOCOL DEVELOPMENT. TASK ORDER 02. 06/17/2024 - 06/16/2029. BASE AND EXERCISE 2 UNITS OF OPTION QUANTITY 1.Department of Health and Human Services$324.4KEnds Jun 16, 202960% recompete estimate
ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE DEVELOPMENT, ASSESSING IMPACT OF VARIANTS ON VACCINE IMMUNOGENICITY, AND ANALYZDepartment of Health and Human Services$126.5MEnds Sep 28, 202930% recompete estimate
BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.Department of Health and Human Services$117.4MEnds Sep 30, 203035% recompete estimate
Recompete percentages and windows are AcornBids estimates, not agency forecasts or guarantees.